These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 10064248)

  • 1. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review.
    Segev S; Yaniv I; Haverstock D; Reinhart H
    Clin Infect Dis; 1999 Feb; 28(2):299-308. PubMed ID: 10064248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study.
    Sieper J; Fendler C; Laitko S; Sörensen H; Gripenberg-Lerche C; Hiepe F; Alten R; Keitel W; Groh A; Uksila J; Eggens U; Granfors K; Braun J
    Arthritis Rheum; 1999 Jul; 42(7):1386-96. PubMed ID: 10403266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.
    Iravani A; Klimberg I; Briefer C; Munera C; Kowalsky SF; Echols RM
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():67-75. PubMed ID: 10225575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury.
    Dow G; Rao P; Harding G; Brunka J; Kennedy J; Alfa M; Nicolle LE
    Clin Infect Dis; 2004 Sep; 39(5):658-64. PubMed ID: 15356779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: the safety profile of tegaserod.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of ciprofloxacin. A review.
    Rahm V; Schacht P
    Scand J Infect Dis Suppl; 1989; 60():120-8. PubMed ID: 2667105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhinoscleroma treated with ciprofloxacin: a case report.
    Avery RK; Salman SD; Baker AS
    Laryngoscope; 1995 Aug; 105(8 Pt 1):854-6. PubMed ID: 7630299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A follow-up safety study of ciprofloxacin users.
    Jick SS; Jick H; Dean AD
    Pharmacotherapy; 1993; 13(5):461-4. PubMed ID: 8247912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin: an overview of adverse experiences.
    Ball P
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():187-93. PubMed ID: 3542945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selected papers from the Sixth International Symposium on Long- Term Clinical Trials. Garmisch-Partenkirchen, West Germany, June 12-15, 1988.
    Control Clin Trials; 1989 Dec; 10(4 Suppl):119S-263S. PubMed ID: 2605961
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of oral ciprofloxacin. An update based on clinical trial results.
    Schacht P; Arcieri G; Hullmann R
    Am J Med; 1989 Nov; 87(5A):98S-102S. PubMed ID: 2686432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome.
    Byren I; Bejon P; Atkins BL; Angus B; Masters S; McLardy-Smith P; Gundle R; Berendt A
    J Antimicrob Chemother; 2009 Jun; 63(6):1264-71. PubMed ID: 19336454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion.
    Biering-Sørensen F; Høiby N; Nordenbo A; Ravnborg M; Bruun B; Rahm V
    J Urol; 1994 Jan; 151(1):105-8. PubMed ID: 8254783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis.
    Daikos GL; Kathpalia SB; Lolans VT; Jackson GG; Fosslien E
    Am J Med; 1988 Apr; 84(4):786-90. PubMed ID: 3135746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics.
    Nix DE; Cumbo TJ; Kuritzky P; DeVito JM; Schentag JJ
    Am J Med; 1987 Apr; 82(4A):146-53. PubMed ID: 3555029
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.